Abstract:Treatment of locally advanced non-small cell lung cancer (NSCLC) remains challenging. The rationale of combining a cyclooxygenase 2 (COX-2) inhibitor with concurrent chemoradiation (CCRT) was based on results of preclinical research and prospective clinical studies; however, no randomized clinical trial has provided evidence of a direct comparison with CCRT alone.To determine the effect of combined selective COX-2 inhibition with standard CCRT on survival among patients with unresectable stage III NSCLC.A single-center, open-label, randomized phase 2 clinical trial was performed among 96 patients who had histologically and cytologically confirmed unresectable stage III NSCLC. Participants were enrolled from November 2011 to August 2015. Data were analyzed from February to October 2018.Patients were randomized to receive thoracic radiation, 60 Gy, for 6 weeks concurrent with etoposide and cisplatin or the same regimen of CCRT combined with 200 mg of celecoxib, taken twice daily.The primary end point was overall survival. The secondary end points were the proportion of patients with treatment-related toxic effects, progression-free survival, and overall survival in subgroups with and without the COX-2 genotype.A total of 100 patients were randomized. Following the exclusion of 4 outliers, 96 participants (96.0%) were analyzed (51 randomized to CCRT alone and 45 randomized to CCRT with celecoxib; mean [SD] age, 60.0 [8.3] years; 73.0 [76.0%] male). The median overall survival time was 32.8 (95% CI, 17.0-48.5) months in the group that received CCRT with celecoxib and 35.5 (95% CI, 25.8-45.2) months in the group that received CCRT alone (P = .88). Celecoxib with CCRT was well tolerated; the incidence of symptomatic radiation pneumonitis was 6.6% (95% CI, 1.4%-18.0%) in the group that received CCRT with celecoxib and 11.8% (95% CI, 4.4%-23.9%) in the group that received CCRT alone (P = .49). Among patients with the high-risk genotype, celecoxib plus CCRT was not associated with higher progression-free survival (hazard ratio, 0.36; 95% CI, 0.13-1.04; P = .05) or overall survival (hazard ratio, 0.50; 95% CI, 0.15-1.72; P = .26) compared with CCRT alone.In unresectable stage III NSCLC, adding celecoxib to concurrent chemoradiation did not improve survival. A smaller, not statistically significant proportion of patients in the CCRT with celecoxib group compared with the CCRT alone group developed symptomatic radiation pneumonitis. Among patients with the high-risk genotype, adding celecoxib to CCRT did not improve overall or progression-free survival.ClinicalTrials.gov identifier: NCT01503385.

The Role of Cox-2 Expression in Locally Advanced Rectal Cancer Treated with Neoadjuvant Concurrent Radiation with Capecitabine/Oxaliplatin and Celecoxib

Comparison of Two Different Neoadjuvant Chemoradiatiotherapy Regimens for Locally Advanced Rectal Cancer: Results of a Phase II, Multicenter, Randomized Trial.

Long-course neoadjuvant chemoradiotherapy with versus without a concomitant boost in locally advanced rectal cancer: a randomized, multicenter, phase II trial (FDRT-002)

Phase II Study of Neoadjuvant Short-Course Radiotherapy Combined with CAPEOX Plus Envafolimab in Patients with Microsatellite Stable Locally Advanced Rectal Cancer: Updated Results of PRECAM Study.

Efficacy of the radiotherapy combined with oxaliplatin and capecitabine in the treatment of local advanced rectal cancer

Expression of cyclooxygenase 2 in colorectal cancer

Effect of Concurrent Chemoradiation with Celecoxib Vs Concurrent Chemoradiation Alone on Survival among Patients with Non–Small Cell Lung Cancer with and Without Cyclooxygenase 2 Genetic Variants

Efficacy and Safety Profile of Celecoxib for Treating Advanced Cancers: A Meta-Analysis of 11 Randomized Clinical Trials

Phase Ii Trial Of Neoadjuvant Chemoradiation With Concomitant Boost Followed By A Coycle Of Xelox In Locally Advanced Rectal Cancer

SONCAR study: A prospective randomized controlled study on optimized neoadjuvant chemotherapy-oxaliplatin plus CRT in patients with locally advanced rectal cancer.

A Phase Ⅱ Clinical Trial of Celecoxib Combined with Platinum-Based Chemotherapy in the Treatment of Patients with Advanced NSCLC As First-Line Treatment

Concomitant boost IMRT-based neoadjuvant chemoradiotherapy for clinical stage II/III rectal adenocarcinoma: results of a phase II study

Role of COX-2 in Carcinogenesis of Colorectal Cancer and Its Relationship with Tumor Biological Characteristics and Patients’ Prognosis

CapOX As Neoadjuvant Chemotherapy for Locally Advanced Operable Colon Cancer Patients: a Prospective Single-Arm Phase II Trial

Application of oxaliplatin combined with capecitabine in preoperative concurrent chemoradiotherapy for locally advanced rectal cancer

[Short-Term Preoperative Treatment of Celecoxib, a Selective Cyclooxygenase-2 Inhibitor, on E-cadherin Expression in Gastric Carcinoma Tissues].

Interim result of phase II, prospective, single-arm trial of long-course chemoradiotherapy combined with concurrent tislelizumab in locally advanced rectal cancer

Effects of cyclooxygenase-2 inhibitor celecoxib on cyclooxygenase-2 gene expression and cisplatin chemosensitivity in human lung adenocarcinoma A549 cell line

Antitumor and anti-metastatic effects of cyclooxygenase-2 inhibition by celecoxib on human colorectal carcinoma xenografts in nude mouse rectum

The Effect of Oxaliplatin Plus Capecitabine in Combination with Radiation for Locally Advanced Lower or Middle Sited Rectal Carcinoma

Oxaliplatin-based Adjuvant Chemotherapy Without Radiotherapy Can Improve the Survival of Locally-Advanced Rectal Cancer.